UPDATE: Oppenheimer Raises PT to $37 on Oracle Following Positive Q2 Results
Oppenheimer reiterated its Outperform rating on Oracle (NASDAQ: ORCL) and increased its price target from $36 to $37.
Oppenheimer said, "We believe Oracle's internally-driven new product-cycles are gaining traction within the base, and as the uptake becomes more meaningful (over the next 12-18 months) it should start yielding greater operating leverage and serve as a catalyst to drive a revaluation of the stock multiple."
Oracle closed at $32.88 on Tuesday.
Latest Ratings for ORCL
|Jul 2016||Atlantic Equities||Downgrades||Overweight||Neutral|
|Jul 2016||BTIG Research||Maintains||Buy|
|Jul 2016||BMO Capital||Upgrades||Market Perform||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.